Urokinase-type plasminogen activator (PLAU) mRNA (PLAU mRNA)

Urokinase-type plasminogen activator (PLAU) mRNA is the messenger RNA transcript that encodes the urokinase-type plasminogen activator (uPA) protein, a key serine protease in the fibrinolytic system (NCBI Gene, 2024). The uPA protein, once translated, catalyzes the conversion of plasminogen to plasmin, which in turn degrades various components of the extracellular matrix and activates other matrix metalloproteinases (UniProt, 2024). Overexpression of PLAU mRNA is a hallmark of many aggressive cancers, where it promotes tumor cell invasion, migration, and metastasis by facilitating the breakdown of tissue barriers (PubMed, PMID: 11507054). Consequently, PLAU mRNA has emerged as a therapeutic target for RNA-based interventions, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), designed to silence uPA expression (PubMed, PMID: 15601762). By reducing the levels of PLAU mRNA, these therapies aim to curtail the proteolytic activity that drives cancer progression and other pathological processes like chronic inflammation and fibrosis (PubMed, PMID: 12110401). Additionally, the regulation of PLAU mRNA stability and translation is a complex process involving various RNA-binding proteins and microRNAs, which are also being explored as potential therapeutic avenues (PubMed, PMID: 17210614). Targeting the mRNA directly offers a way to inhibit the uPA system before the protein is even synthesized, potentially providing a more potent blockade of the pathway in metastatic disease (PubMed, PMID: 10411107).

Other names

uPA mRNAUrokinase-type plasminogen activator mRNAURK mRNAUrokinase mRNA

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript to prevent the translation of the urokinase-type plasminogen activator (uPA) protein.